Results 1 to 10 of about 16,120 (219)

Management of transthyretin amyloidosis [PDF]

Swiss medical weekly, 2021
Transthyretin amyloidosis (ATTR amyloidosis) is a disease caused by deposition of transthyretin fibrils in organs and tissues, which causes their dysfunction. The clinical heterogeneity of ATTR amyloidosis and the variable presentation of symptoms at early disease stages, historically meant treatment delays. Diagnostic tools and therapy options of ATTR
Condoluci, Adalgisa, Théaudin, Marie, Schwotzer, Rahel, Pazhenkottil, Aju P, Arosio, Paolo, Averaimo, Manuela, Bacher, Ulrike, Bode, Peter, Cavalli, Andrea, Dirnhofer, Stefan, Djerbi, Nadia, Dobner, Stephan, Fehr, Thomas, Garofalo, Maura, Gaspert, Ariana, Gerull, Sabine, Heimgartner, Raphael, Hübers, Annemarie, Jung, Hans H, Kessler, Chiara, Knöpfel, Raphael, Laptseva, Natallia, Magini, Giulia, Manka, Robert, Mazzucchelli, Luca, Meyer, Martin, Mihaylova, Violeta, Monney, Pierre, Mylonas, Alessio, Nkoulou, René, Pabst, Thomas, Pfister, Otmar, Rüfer, Axel, Schmidt, Adrian, Seeger, Harald, Stämpfli, Simon F, Stirnimann, Guido, Suter, Thomas, Treglia, Giorgio, Tzankov, Alexandar, Vetter, Friederike, Zweier, Markus, Flammer, Andreas J, Gerber, Bernhard   +43 more
core   +6 more sources

Restrictive Atrial Dysfunction in Cardiac Amyloidosis: Differences between Immunoglobulin Light Chain and Transthyretin Cardiac Amyloidosis Patients [PDF]

Biomedicines, 2022
Background: In cardiac amyloidosis, the prevalence of thromboembolic events and atrial fibrillation is higher in transthyretin amyloidosis compared to immunoglobulin light chain amyloidosis.
Mathijs O. Versteylen, Maaike Brons, Arco J. Teske, Marish I. F. J. Oerlemans   +3 more
doaj   +2 more sources

Cardiac Transthyretin Amyloidosis: Hidden in Plain Sight

Case Reports in Medicine, 2021
Amyloidosis is an underappreciated medical condition with symptoms camouflaging as common medical comorbidities leading to its underdiagnosis due to its systemic involvement.
Constantine N. Logothetis, Joel Fernandez, Damian A. Laber   +2 more
doaj   +2 more sources

Transthyretin Amyloidosis: Chaperone Concentration Changes and Increased Proteolysis in the Pathway to Disease. [PDF]

PLoS ONE, 2015
Transthyretin amyloidosis is a conformational pathology characterized by the extracellular formation of amyloid deposits and the progressive impairment of the peripheral nervous system.
Gonçalo da Costa, Cristina Ribeiro-Silva, Raquel Ribeiro, Samuel Gilberto, Ricardo A Gomes, António Ferreira, Élia Mateus, Eduardo Barroso, Ana V Coelho, Ana Ponces Freire, Carlos Cordeiro   +10 more
doaj   +3 more sources

Advances in the treatment of transthyretin amyloidosis. [PDF]

eGastroenterology
This review aims to provide a comprehensive overview of the existing therapeutic options for managing neuropathic and/or cardiac manifestations associated with transthyretin amyloidosis (ATTR), along with investigational therapeutic candidates under evaluation in ongoing clinical trials.
Anan I.
europepmc   +5 more sources

Transthyretin amyloidosis [PDF]

Nursing, 2020
Abstract: Cardiac amyloidosis is a poorly understood cause of heart failure and is often undiagnosed. Recent advances in diagnostic testing and understanding of the disease have enhanced the ability of clinicians to detect this disease and provide patients with appropriate treatment.
Renáta Aiglová, Miloš Táborský, Pavla Flodrová, Alexander Schee   +3 more
openaire   +3 more sources

Transthyretin cardiac amyloidosis

Cardiovascular Research, 2022
AbstractTransthyretin cardiac amyloidosis (ATTR-CA) is an increasingly recognized cause of heart failure (HF) and mortality worldwide. Advances in non-invasive diagnosis, coupled with the development of effective treatments, have shifted ATTR-CA from a rare and untreatable disease to a relatively prevalent condition that clinicians should consider on a
Aldostefano Porcari, Marianna Fontana, Julian D Gillmore   +2 more
openaire   +4 more sources

Multidisciplinary Approaches for Transthyretin Amyloidosis [PDF]

Cardiology and Therapy, 2021
Amyloidosis caused by systemic deposition of transthyretin (TTR) is called ATTR amyloidosis and mainly includes hereditary ATTR (ATTRv) amyloidosis and wild-type ATTR (ATTRwt) amyloidosis. Until recently, ATTRv amyloidosis had been considered a disease in the field of neurology because neuropathic symptoms predominated in patients described in early ...
Haruki Koike, Takahiro Okumura, Toyoaki Murohara, Masahisa Katsuno   +3 more
openaire   +2 more sources

Transthyretin Amyloidosis and the Kidney [PDF]

Clinical Journal of the American Society of Nephrology, 2012
Summary The amyloidoses are protein-misfolding disorders associated with progressive organ dysfunction. Immunoglobulin light chain is the most common, amyloid A the longest recognized, and transthyretin-associated amyloidosis (ATTR) the most frequent inherited systemic form.
Luísa, Lobato, Ana, Rocha
openaire   +2 more sources

Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient

JACC: Case Reports, 2021
Currently adopted diagnostic flow charts consider transthyretin and light-chain cardiac amyloidosis as mutually exclusive. Here, we report for the first time, to our knowledge, the demonstration of a biopsy-proven dual pathology in an 80-year-old man ...
Giuseppe Vergaro, MD, PhD, Vincenzo Castiglione, MD, Roberta Poletti, MD, Gabriele Buda, MD, Angela Pucci, MD, PhD, Veronica Musetti, BSc, Dario Genovesi, MD, Alberto Aimo, MD, Claudio Passino, MD, Michele Emdin, MD, PhD   +9 more
doaj   +1 more source